ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study

Hou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Chen, Jing; Zhang, Baishen; You, Zhixuan; Liu, Qing; Chen, Likun*佛山市第一人民医院; 广州医学院; 南方医科大学; 中山大学; 1; 东莞市人民医院
JAMA Network Open2023-2DOI: 10.1001/jamanetworkopen.2022.55050
4被引6阅读
引用收藏
分享

摘要

IMPORTANCE Use of tyrosine kinase inhibitors (TKIs) is the standard therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with brain metastases. Several studies have shown that adding chemotherapy to EGFR-TKIs could improve progression-free survival (PFS) in patients with EGFR-mutant advanced NSCLC; however, the efficacy of these agents in patients with brain metastases remains unclear. @@@ OBJECTIVE To investigate the efficacy and safety of gefitinib plus chemotherapy (pemetrexed with platinum) compared with gefitinib alone in patients with untreated EGFR-mutant NSCLC brain metastases. @@@ DESIGN, SETTING, AND PARTICIPANTS This open-label prospective, multicenter, phase 3 randomized clinical trial was conducted in 6 centers in China from January 13, 2016, to August 27, 2021. The median follow-up time was 21.1 months (IQR, 13.5-31.8 months). Patients with untreated confirmed brain metastases and EGFR-sensitive mutated NSCLC were enrolled. @@@ INTERVENTIONS The eligible patients were randomly assigned (1:1) to receive gefitinib plus chemotherapy or gefitinib alone. @@@ MAIN OUTCOMES AND MEASURES The primary end point was intracranial PFS; secondary end points included PFS, overall survival (OS), intracranial objective response rate, overall objective response rate, and safety. Intention-to-treat analysis was performed. @@@ RESULTS A total of 161 patients (87 [54.0%] women; mean [SD] age, 55 [9.8] years; range, 26-80 years) were enrolled and randomized to receive gefitinib (n = 81) or gefitinib plus chemotherapy (n = 80). The median intracranial PFS was 15.6 months (95% CI, 14.3-16.9 months) in the gefitinib plus chemotherapy group vs 9.1 months (95% CI, 8.0-10.2 months) in the gefitinib group (hazard ratio, 0.36; 95% CI, 0.25-0.53; P <.001). Similarly, the median PFS was significantly longer with gefitinib plus chemotherapy than gefitinib alone (16.3; 95% CI, 14.4-18.2 months vs 9.5; 95% CI, 8.3-10.8 months; P <.001). Gefitinib plus chemotherapy had a better intracranial objective response rate (85.0%; 95% CI, 77.0%-93.0% vs 63.0%; 95% CI, 52.2%-73.7%; P =.002) and overall objective response rate (80.0%; 95% CI, 71.0%-89.0% vs 64.2%; 95% CI, 53.5%-74.9%; P =.03) than gefitinib alone. At data cutoff, the median OS was also significantly longer in the gefitinib plus chemotherapy group vs the gefitinib group (35.0 vs 28.9 months; hazard ratio, 0.65; 95% CI, 0.43-0.99; P =.04). Grade 3 or worse adverse events were more common with gefitinib plus chemotherapy, most of which were manageable. @@@ CONCLUSIONS AND RELEVANCE In this randomized clinical trial, gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS compared with gefitinib alone in patients with untreated EGFR-mutant NSCLC brain metastases and could be an optional first-line treatment for these patients.

学科与关键词

关键词
1ST-LINE TREATMENTIII TRIALMUTATIONERLOTINIBSURVIVALNSCLCCOMBINATIONCARBOPLATINPACLITAXELTHERAPY
相关
加载中…
  • First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
    Song, Yaowen; Lin, Shuiyu; Chen, Jun; Dang, Jun*BMC CANCER, 2023, 23(1): 1043.被引 1
  • Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFRmutated non-small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
    Chen, Likun; Hou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Zhang, Baishen; Chen, Jing; You, ZhixuanAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
  • Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.*; Janne, P. A.; Cheng, Y.; Yang, J. C. -H.; Yanagitani, N.; Kim, S-W; Sugawara, S.; Yu, Y.; Fan, Y.; Geater, S. L.; Laktionov, K.; Lee, C. K.; Valdiviezo, N.; Ahmed, S.; Maurel, J-M; Andrasina, I; Goldman, J.; Ghiorghiu, D.; Rukazenkov, Y.; Todd, A.; Kobayashi, K.New England Journal of Medicine, 2023, 389(21): 1935-1948.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
JAMA Network Open
发表日期
2023-02
卷期
第 6 卷, 第 2 期
页码
e2255050
DOI
10.1001/jamanetworkopen.2022.55050
成果收录
SCIE
资助标注
National Natural Science Foundation of China [82072559]; Natural Science Foundation of Guangdong Province [2022A1515012582]; Sun Yat-sen University Young Teacher Plan [19ykpy179]; Guangzhou Science and Technology Program [202002020074]

作者

  • H

    Hou, Xue (第一作者)

    sun yat sen univ

  • L

    Li, Meichen

    sun yat sen univ

查看全部 12 位作者收起作者
  • W

    Wu, Guowu

  • F

    Feng, Weineng

    first peoples hosp foshan

  • S

    Su, Jin

    southern med univ

  • J

    Jiang, Honghua

  • J

    Jiang, Guanming

    dongguan peoples hosp · southern med univ

  • C

    Chen, Jing

    sun yat sen univ

  • Z

    Zhang, Baishen

    sun yat sen univ

  • Y

    You, Zhixuan

    1 · guangzhou med univ

  • L

    Liu, Qing

    sun yat sen univ

  • C

    Chen, Likun (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417